# Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

> **NCT06308913** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 10 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** INCB081776
- **DRUG:** Pembrolizumab
- **RADIATION:** Palliative RT

## Key facts

- **NCT ID:** NCT06308913
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-18
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-08-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06308913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06308913, "Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06308913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*